Q-omics provides the consensus-scored FGFR1 profile across patient tissues and cancer cell-line models. FGFR1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, FGFR1 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, FGFR1 RNA expression shows 17,897 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, and THYM as cancer lineages where FGFR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FGFR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FGFR1 survival associations across molecular data types. FGFR1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FGFR1 RNA expression–survival associations across cancer types. High FGFR1 expression shows unfavorable associations in BLCA, UVM and LGG, but favorable associations in HNSC, CESC and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for FGFR1 RNA expression.
This table summarizes FGFR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FGFR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FGFR1 shows lower tumor expression in BLCA, COAD, BRCA, THCA and LUAD and higher tumor expression in CHOL. The BLCA box plot shows higher FGFR1 RNA expression in normal versus tumor tissue (log2 FC = −3.100, t-test p < 0.001).
This table shows molecular features associated with FGFR1 in patient tissues and cancer cell lines. In patient samples, FGFR1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FGFR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
